Compare NNBR & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNBR | TRDA |
|---|---|---|
| Founded | 1980 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.7M | 275.3M |
| IPO Year | 1996 | 2021 |
| Metric | NNBR | TRDA |
|---|---|---|
| Price | $3.91 | $4.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $6.67 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 2.4M | 376.9K |
| Earning Date | 10-28-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.60 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $770,657,000.00 | $25,421,000.00 |
| Revenue This Year | $13.55 | N/A |
| Revenue Next Year | $8.08 | $87.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.10 | $4.11 |
| 52 Week High | $4.65 | $16.45 |
| Indicator | NNBR | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 53.10 | 38.64 |
| Support Level | $3.56 | $4.11 |
| Resistance Level | $3.86 | $7.89 |
| Average True Range (ATR) | 0.27 | 0.50 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 65.61 | 22.80 |
NN Inc is a diversified industrial company that combines engineering and production capabilities with materials science expertise to design and manufacture high-precision components and solutions. The company operates through two segments: Mobile Solutions, which generates maximum revenue and focuses on the automotive, general industrial, and medical end markets, manufacturing tight-tolerance components used in battery electric, hybrid electric, and internal combustion engine vehicles, braking, transmissions, fuel systems, HVAC, and diesel systems; and Power Solutions, which focuses on the electrical, general industrial, automotive, medical, and aerospace and defense end markets and manufactures high-precision metal components, assemblies, contact assemblies, and precision stampings.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.